Annexon Highlights Strategic Focus to Advance Four Flagship
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...
San Francisco United States Chelcie Lister Sheryl Seapy Strategic Communications Securities Exchange
Source: globenewswire.com